Short communicationThe safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteers
Section snippets
Acknowledgements
We are grateful to the volunteers in this study for their dedication, passion and willingness to participate in the critical role of testing an experimental HIV vaccine. We express our appreciation to the members of our scientific advisory board, DAIDS-NIH and in particular Drs. Stuart Shapiro, Alan Fix, Dale Lawrence of DAIDS-NIH, and Francis Ennis, UMMS for their insightful comments, discussions and scientific expertise in bringing this vaccine from the concept stage to human clinical trials.
References (35)
- et al.
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime–protein boost HIV-1 vaccine in healthy human volunteers
Vaccine
(2008) - et al.
Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype
Virology
(2006) - et al.
Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits
Vaccine
(2006) - et al.
QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans
Vaccine
(2001) - et al.
A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
Vaccine
(2000) - et al.
A review of vaccine research and development: the human immunodeficiency virus (HIV)
Vaccine
(2006) - et al.
Delayed hypersensitivity, immune deviation, antigen processing and T-cell subset selection in syphilis pathogenesis and vaccine design
Immunol Today
(1993) - et al.
Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites
Vaccine
(2002) - et al.
ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines
Vaccine
(2004) - et al.
Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma
Vaccine
(1994)
Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults
Vaccine
New hope for an AIDS vaccine
Nat Rev Immunol
Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines
J Infect Dis
Safety and immune responses to a DNA-based human immunodeficiency virus (HIV) type I env/rev vaccine in HIV-infected recipients: follow-up data
J Infect Dis
Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects
J Acquir Immune Defic Syndr
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses
J Exp Med
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
J Infect Dis
Cited by (48)
An immunopotentiator, ophiopogonin D, encapsulated in a nanoemulsion as a robust adjuvant to improve vaccine efficacy
2018, Acta BiomaterialiaCitation Excerpt :Recent research has shown that QS-21, a typical representative of saponins, has robust adjuvant activity in eliciting antibody and cell-mediated immune responses [8,9]. As a result, QS-21 is now a candidate adjuvant for many trial vaccines, including vaccines for HIV-1 [10], cancer [11], hepatitis B [11], malaria and others [12]. However, QS-21 has limited use in clinical applications due to certain deficiencies, such as a low Th2 immune response, strong hemolytic effects and very scarce sources [9,13].
Synthesis of the hexacyclic triterpene core of the jujuboside saponins via tandem Wolff rearrangement–intramolecular ketene hetero-Diels–Alder reaction
2018, TetrahedronCitation Excerpt :They exhibit a wide range of bioactivities including immunoadjuvant, anticancer, antifungal, antibacterial, and antisweet activities.1–3 In particular, jujuboside A (2) has been reported to generate higher antibody titers in mouse vaccinations and lower in vitro toxicity compared to QS-21,2,3 another saponin immunoadjuvant that is a component of the Mosquirix (RTS,S/AS01) malaria vaccine4 and Shingrix shingles vaccine5 and has been investigated as the immunoadjuvant of choice in numerous other vaccine clinical trials.6–12 Based on our laboratory's long-standing interest in saponin immunoadjuvants13–20 we initiated a research program toward the total synthesis of jujuboside A to enable detailed structure–activity relationships studies.
An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
2017, Trends in Pharmacological SciencesCitation Excerpt :The linear tetra-saccharides terminal domain has two isomeric units: QS-21-apiose and QS-21-xylose [57,58]. QS-21 has been shown to exert adjuvant activity in vaccine formulations against cancer [59,60], infections such as malaria [61,62], AIDS [63], hepatitis [64,65], and TB [66], and also against Alzheimer’s disease [67]. The mechanism of action of QS-21 at the molecular level remains unclear.
Human Immunodeficiency Virus Vaccines
2017, Plotkin's Vaccines